A study published in the Journal of Hepatology looked at a DAA regimen in patients with a history of poor adherence or treatment interruption, as well as in patients with HIV/HCV coinfection. The RESOLVE study aimed to assess the safety and efficacy of this combination in patients with HCV infection who had relapsed following DAA therapy, regardless of HIV infection or previous treatment course. They found that retreating with DAAs is safe and effective for HCV reinfection.
Retreatment with 12 weeks of SOF/VEL/VOX was safe and effective in patients with relapsed HCV following initial combination DAA-based treatment. Treatment response was not affected by HIV coinfection or previous treatment course.
Twelve weeks of the combination of direct-acting antivirals (SOF/VEL/VOX) was safe and effective in patients with relapsed hepatitis C virus infection who had previously received combination therapy with direct-acting antivirals. Treatment response was not diminished by HIV coinfection, or non-completion of previous direct-acting antiviral-based therapy.